According to CNBC, the “new Bull Market” will officially get underway when the S&P 500 closes above the 4192 level, achieving gains of more than 20% over the past year. It’s less than a sand wedge away at this point.
This is particularly important given how we keep hearing from “The Street” about the imminent recession just around the corner, the geopolitical tension that will inevitably draw everyone into WWIII, or the re-emergence of the 1970’s style “inflation genie” and the endless series of rate hikes that characterize our collective future.
Who knows whether these prophecies will come to pass. All we know now is that their general acceptance has a ton of people short and flat and a ton of professional money on the sidelines.
Whatever method of analysis you use in markets, being on the same side as the consensus view when the consensus view is extremely skewed toward one side is rarely a good bet. In fact, it has never been a good bet. Just ask Warren Buffet, Jim Rogers, Bill Ackman, or George Soros—all investors with tremendous track records tethered to strategies that depend upon going against the tide of opinion when the tide is unified in lockstep.
Right now is just such a time.
The American Association of Individual Investors has given us more bears than bulls for 79 of the past 82 weeks (a record), we have near all-time record PUT ownership, and near all-time record short interest in equity index futures among smaller non-professional investors. At the same time, according to the BofA Fund Manager Survey, big, long-only/equity-only funds are sitting at 5.6% cash levels, which is much higher than average, suggesting huge reserves of capital still on the sidelines.
In other words, the crowd is short and flat, with very few people sticking their necks out to speculate on the long side. Yet, the market continues to make progress in what the technicians are now calling a new bull market.
Eventually, this type of configuration tends to historically lead to a transition in sentiment where the crowd chases the market, and stocks break out as people fold their bearish hands and plow into new equity exposure.
If we take this analysis at face value, then it’s time to start hunting for outsized growth themes. While you can put your finger on a few good candidates—artificial intelligence, robotics, genomics, and frontier technology in the telecom network hardware space—many of these themes are already crowded.
But there are a few themes with huge growth potential that the crowd has yet to discover. One such theme is men’s health. Recent market research projects a staggering compound annual growth rate (CAGR) of 15% by 2029, signaling powerful upside potential for investors.
A confluence of factors, including a rise in men’s health awareness, a paradigm shift in societal norms that emphasize self-care, and ground-breaking developments in medical technology and research, are just a few of the factors driving the growth in this sector.
MGRX: A Closer Look
The men’s health market encompasses a diverse range of products and services, including pharmaceuticals, dietary supplements, fitness equipment, personal care products, telehealth services, and tailored wellness programs.
These offerings cater to various aspects of men’s health, including physical fitness, mental wellness, and nutritional support.
Mangoceuticals, Inc. (NASDAQ: MGRX) is a rising star in this space precisely because it has adopted a unique angle on marketing to this diverse yet coherent end market. That approach has started to catch fire as shares of the stock ramp higher, up as much as 60% in the past five days of trading.
MGRX specializes in developing, marketing, and selling cutting-edge men’s health and wellness products. Through its secure telemedicine platform, ‘MangoRx,’ the company provides convenient access to its flagship product, Mango—an innovative medication specifically designed to treat the symptoms of erectile dysfunction (ED).
The company recently concluded its successful IPO on the Nasdaq, generating $5,000,000 in gross proceeds. These funds are being put to use to drive product awareness and operational expansion as the company launches its flagship product: Mango, a groundbreaking solution designed to address men’s unique concerns.
Unlike many competitors offering generic medications, Mangoceuticals takes pride in creating its own expertly formulated ED compounds, ensuring a superior experience for customers. Crafted with FDA-approved ingredients, Mango combines a selection of compounds to target the challenges men face in intimate situations.
MGRX Gets in Gear
The stock’s explosive action over the past week appears to be tied to growth in investor awareness of the company’s flagship product launch fueled by its aggressive marketing activity.
The company has recently beefed up its advisory board with new talent, rang the bell on the Nasdaq exchange in front of a television audience in the millions, and launched a new viral video ad campaign: “Some Things Are Better Hard”.
The campaign centers around a single full-length video made of multiple short videos, all designed to go viral. It’s definitely worth a watch.
According to the company, the whole package will be widely distributed, together as a whole and separately, across multiple social media platforms, including, but not limited to, Facebook, Instagram, Snapchat, TikTok, YouTube, Google, and Twitter.
The real kicker is the ‘angle’ MGRX is taking in its marketing strategy: The composition is designed to reinforce the central theme that “Some Things Are Better Hard”, leveraging humor and an open and confident framing of the pursuit of male health and personal improvement to defuse social taboos and normalize ED as a commonly shared functional obstacle to healthy male experiences.
In other words, the market context is finally conducive to the eruption of new bull market speculative stars with big growth foundations already laid out.
MGRX is a perfect example of this phenomenon. The company has a fresh angle on grabbing market share in a $31 billion space growing at 15% CAGR—strip the taboo out of the equation and provide men and couples with a path to peak quality of life. It’s a simple recipe. But MGRX looks to have a monopoly on that messaging avenue.
So far, the market is responding.
